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Gefitinib (IRESSA), an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, has antitumour activity in the advanced
non-small-cell lung cancer (NSCLC) setting. However, in chemotherapy-naı ¨ve patients with advanced NSCLC, the addition of
gefitinib to standard chemotherapy regimens failed to increase survival. These results suggest the need for improved patient selection
and combination rationales for targeted therapies. We have identified subpopulations of an adenocarcinoma cell line that are
naturally resistant to gefitinib, and have analysed the cDNA expression profiles, genomic status of EGFR gene and the effect of
gefitinib on signalling pathways in these cell lines in order to identify key mechanisms for naturally acquired resistance to gefitinib.
Gefitinib-resistant subpopulations demonstrated increased Akt phosphorylation (not inhibited by gefitinib), reduced PTEN protein
expression and loss of the EGFR gene mutation when compared with parental cell lines. These differences in Akt and PTEN protein
expression were not evident from the cDNA array profiles. These data suggests that (1) the EGFR gene mutation may be possibly
lost in some cancer cells with other additional mechanisms for activating Akt, (2) reintroduction of PTEN or pharmacological
downregulation of the constitutive PI3K–Akt-pathway activity may be an attractive therapeutic strategy in cancers with gefitinib
resistance.
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The epidermal growth factor receptor (EGFR) is a 170-kDa protein
composed of an extracellular ligand-binding domain, a short
transmembrane domain and an intracellular domain with intrinsic
tyrosine kinase (TK) activity (Cohen et al, 1982; Carpenter and
Cohen, 1990). High expression of EGFR has been reported in
various epithelial malignant tumours, including lung cancer, and
has been shown to play a causal role in disease progression
(Ozanne et al, 1986; Haeder et al, 1988). Epidermal growth factor
receptor is, therefore, a promising molecular therapeutic target in
various tumour types, including lung cancer.
Gefitinib (IRESSA) (4-(3-chloro-4-fluoroanilino)-7-methoxy-6-
(3-morpholinopropoxy)-quinazoline) is an orally active EGFR-TK
inhibitor that inhibits EGFR signalling (Rusch et al, 1993; Salomon
et al, 1995). Phase I trials of gefitinib in patients with solid tumours
refractory to standard chemotherapy have shown good tolerability
and evidence of antitumour activity (Ferry et al, 2000; Ranson
et al, 2002). IDEAL (IRESSA Dose Evaluation in Advanced Lung
cancer) 1 and 2 were randomised phase II trials in patients with
non-small-cell lung cancer (NSCLC) refractory to platinum-based
chemotherapy. These trials demonstrated that gefitinib was active
and generally well tolerated: response rates were 18.4 and 11.8%,
respectively, and the predominant toxicities were mild or moderate
skin rash and diarrhoea (Fukuoka et al, 2003; Kris et al, 2003). The
INTACT (IRESSA NSCLC Trial Assessing Combination Treatment)
1 and 2 phase III trials compared first-line chemotherapy with and
without gefitinib in patients with advanced NSCLC and demon-
strated similar survival outcomes in both treatment arms
(Giaccone et al, 2004; Herbst et al, 2004). These data indicate that
improved patient selection and combination strategies are
required for optimal utility of this targeted therapy.
Gefitinib exerts antitumour activity through inhibition of EGFR-
TK, but its antitumour activity is not significantly correlated with
tumour cell EGFR expression (Bailey et al, 2003). Recently,
differences in the frequency of activating mutations in the EGFR
gene between gefitinib responders and nonresponders were
reported and these EGFR mutations seem to be predictive markers
for sensitivity to gefitinib (Lynch et al, 2004; Paez et al, 2004). We
examined sensitivity to gefitinib in NSCLC cell lines using the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-tetrazolium bromide) cell prolif-
eration assay and identified a parent adenocarcinoma cell line,
PC9, that was sensitive to gefitinib and two subpopulations, PC9/f9
and PC9/f14, that were resistant. These subpopulations of PC9
were established by artificial metastasis methods and resistance to
Received 5 August 2004; revised 5 January 2005; accepted 10 March
2005
*Correspondence: Dr A Gemma; E-mail: agemma@nms.ac.jp
British Journal of Cancer (2005) 92, 1711–1719
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sgefitinib was therefore acquired naturally, without exposure to
gefitinib. In order to identify additional key molecules involved in
gefitinib resistance, we analysed expression profiles using cDNA
array and genomic status of the EGFR gene in the parent cell line
and subpopulations, and examined the effect of gefitinib on the
downstream mediators of EGF-mediated signalling PI3K–Akt and
Ras/MEK/Erk pathways (Olayioye et al, 2000).
MATERIALS AND METHODS
Cell lines
Using the MTT assay, we analysed the growth-inhibitory effect of
gefitinib on nine NSCLC cell lines: A549, PC3, PC7, PC9, PC9/f9,
PC9/f14 and PC14 adenocarcinoma cell lines, Lu65 large-cell
carcinoma cell line and LK-2 squamous-cell carcinoma cell line.
PC9/f9 (Takenaka et al, 2000) and PC9/f14 (Gemma et al, 2001) are
highly metastatic sublines of PC9 established at Nippon Medical
School using artificial metastasis methods. In an attempt to
elucidate potential mechanisms of resistance to gefitinib, we
evaluated cDNA expression profiles and their relationship to
gefitinib resistance. We also specifically examined the effect of
gefitinib on the PI3K–Akt and Ras/MEK/Erk pathways in PC9,
PC9/f9 and PC9/f14 cells.
Drugs and growth-inhibition assay
Gefitinib was provided by AstraZeneca, Macclesfield, UK and
dissolved in dimethyl sulphoxide (DMSO) for in vitro studies. We
used the colourimetric MTT assay (tetrazolium dye assay) to
examine the activity of gefitinib on NSCLC cell lines (Mosmann,
1983). Cell suspensions (200ml1 10
5 cellsml
 1) were seeded into
the wells of a 96-well microtitre plate and 10ml of drug solution
(various concentrations) was added. After incubation for 72h at
371C, 20ml of MTT solution (5mgml
 1 in phosphate-buffered
saline) was added to each well and incubated for a further 4h at
371C. After centrifugation at 1500r.p.m. for 5min, the medium was
aspirated from each well and 200ml of DMSO was added to dissolve
the formazan. The IC50 value was defined as the concentration
needed for a 50% reduction in absorbance (560nm) based on
survival curves.
RNA isolation, cDNA array hybridisation and analysis of
hybridisation signals
Total RNA was isolated from each cell line using standard
protocols described previously (Gemma et al, 1996, 1998).
Messenger RNA was then purified from total RNA by incubation
with oligo-dT-magnetic beads (Toyobo Co., Osaka, Japan). The
ElectorGene Array System (GeneticLab Co. Ltd, Sapporo, Japan)
was used for filter-based cDNA array analysis, as previously
reported (Gemma et al, 2001). In this analysis, 1300 species of
human DNA fragments, including cancer-related and drug-
resistance-associated genes, as well as housekeeping and non-
mammalian genes as negative controls, are spotted in duplicate on
a filter. The probes were prepared by reverse transcription
(Reverse Transcriptase, ReverTraAce (Toyobo Co., Osaka, Japan)),
with a random 9mer (Toyobo Co., Osaka, Japan) and 5mg of poly
A RNA. The probes were labelled with biotin by incorporation of
biotin-16-deoxyuracil triphosphate during the synthesis of cDNA.
The filters were preincubated in 20ml of PerfectHyb (Toyobo Co.,
Osaka, Japan) at 681C for 30min. The biotin-labelled probes were
denatured and added to the prehybridisation solution and the
filters were incubated overnight at 681C in the hybridisation
mixture. After washing, specific signals on the filters were detected
by the Imaging High-Chemilumi-Detection kit (Toyobo Co.,
Osaka, Japan). CDP-Star substrate (Tropix, Bedford, MA, USA)
was used as the chemiluminescence substrate, and a chemilumi-
nescence image of the filter was acquired by Fluor-S (Bio-Rad,
Hercules, CA, USA). Gene-expression images were quantified by
measuring the intensity of the signals using Imagene (BioDiscov-
ery, Los Angeles, CA, USA) and filter signal intensity was analysed
by the ElectorGene Finding System (GeneticLab Co. Ltd, Sapporo,
Japan). The background threshold was set at a level three-fold
higher than the negative control. Signal intensities were normal-
ised by comparison with the expression of housekeeping genes,
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and beta-
actin. A three-fold difference in gene expression among the
subpopulations and the parent cell line was considered to be
significant, on the basis of the company’s recommendation
(Toyobo Co., Osaka, Japan).
Effect of gefitinib on PI3K–Akt and Ras/MEK/Erk
pathways in PC9, PC9/f9 and PC9/f14 cells
Exposure to gefitinib PC9, PC9/f9 and PC9/f14 cells were serum-
starved and treated with various concentrations of gefitinib (0, 5,
50, 500 and 5000ngml
 1) for 2h before exposure to 10ngml
 1
EGF (BA-53) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
5min.
Western blot analysis Lysis buffer containing 1% Triton X and
1% NP40 was added to the cells before sonication in a POLYTRON
homogenizer (KINEMATICA, Littau-Lucerne, Switzerland). The
lysates were cleared by centrifugation at 14000r.p.m. for 20min,
and then 10ml of lysate containing 10mg of protein were separated
by SDS–polyacrylamide gel electrophoresis (PAGE). After
PAGE, the proteins were transferred to nitrocellulose membranes
and blotted with the following primary antibodies: PTEN A2B1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and Akt,
phospho-Akt (Ser473), p38 MAP kinase and phospho-p38 MAP
kinase (Thr180/Tyr182) (all Cell Signaling Technology, Beverly,
MA, USA). The membranes were then incubated with peroxidase-
conjugated secondary antibodies and protein was detected with
the ECL Western blotting detection reagents (Amersham,
Buckinghamshire, UK) (Naishiro et al, 2001) and film-processor
FPM100 film (Fuji Photo Film). These images were quantified
by measuring the intensity of the signals using NIH Image
(ImageJ1.32j).
Genomic DNA analysis of the PTEN gene by polymerase
chain reaction
From each genomic DNA sample, all exons of the PTEN gene
were amplified separately with the polymerase chain reaction
(PCR) primers previously described (Hosoya et al, 1999) using the
Gene Amp XL PCR kit (Perkin Elmer/Roche, Branchburg, NJ,
USA). Polymerase chain reaction conditions for genomic
DNA analysis were as follows: 40 cycles at 941C for 40s, at 601C
for 30s and at 681C for 90s, followed by 681C for 8min. Each
reaction mixture contained 1  XL buffer, 200mM deoxynucleotide
triphosphate, 1100mM Mg(OAc)2, 0.5U rTth DNA polymerase XL,
0.3mM of each primer (one of each pair) (Hosoya et al, 1999) and
25ng of genomic DNA. Polymerase chain reaction products were
loaded on 1.2% agarose gels. After electrophoresis, the gels were
analysed.
Mutation analysis of the EGFR gene
Polymerase chain reaction–single strand conformation poly-
morphism (PCR–SSCP) analysis was performed as previously
described (Gemma A, et al, 1996, 1998). Each of the three exons
(18, 19 and 21) of the EGFR gene was amplified separately using
reported PCR primers (Lynch et al, 2004). Polymerase chain
reaction was performed using the Gene AMP XL PCR kit (Perkin–
Elmer Corp./Roche, Branchburg, NJ, USA) as described above. The
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Mg(OAc)2, 200mM deoxynucleotide triphosphate, 0.1mM of each
primer labelled with 5-IAF (Amersham Pharmacia Biotech,
Uppsala, Sweden ), 0.5U of rTth DNA polymerase and 25ng of
genomic DNA. The 5-IAF-labelled PCR products were denatured,
cooled on ice, and loaded on neutral 6% polyacrylamide gels with
or without 5% (volvol
 1) glycerol. Following electrophoresis, the
gels were analysed using the FluorImager 595 (Amersham
Pharmacia Biotech, Uppsala, Sweden). DNA sequence analysis
was performed as previously described (Gemma A, et al, 1996,
1998). Aberrant bands were cut from the gel and further amplified
by PCR using sequencing primers with the M13 sequence
(TGTAAAACGACGGCCAGT) added to the appropriate PCR
primers. Sequencing reaction was performed, and the products
were purified and sequenced using a fluorescent automated
sequencer (Perkin–Elmer Corp./Applied Biosystem, Inc., Foster
City CA, USA).
Multicolour fluorescent in situ hybridisation (FISH)
analyses of metaphase preparations from cancer cell line
subpopulation
Multicolour-FISH on metaphase preparations was performed using
Spectra Vysion probes according to the instructions of the
manufacturer (Vysis, Downers Grove, IL, USA). Images were
visualised by an epifluorescence microscope (Zeiss, Oberhochen,
Germany) and analysed using an Applied Imaging CytoVision
Work station (Newcastle, UK, USA). A total of 20 metaphase cells
were analysed in each subpopulation.
RESULTS
Effect of gefitinib on cell growth in vitro
The IC50 values of gefitinib on nine NSCLC cell lines, as
determined by the MTT assay, are summarised in Table 1. In
accordance with the minimal steady-state concentration reported
in the clinical trial (264ngml
 1; 0.59mM), PC9 and A549 seemed to
be sensitive to gefitinib. Interestingly, two subpopulations of the
PC9 cell line, PC9/f9 and PC9/f14, showed resistance to gefitinib
even though the parent cell line was sensitive. A highly metastatic
human lung adenocarcinoma cell line, PC9/f9, was established in
an experimental metastasis model by repeated inoculation of PC9
Table 1 In vitro growth-inhibitory activity of gefitinib on NSCLC cell lines
in the MTT assay
Cell line Cell type IC50 (lM)
PC9 Adenocarcinoma 2.0 10
 3
PC9/f9 Highly metastatic subpopulation of PC9 420
PC9/f14 Highly metastatic subpopulation of PC9 19
A549 Adenocarcinoma 1.8 10
 2
PC7 Adenocarcinoma 420
PC14 Adenocarcinoma 8.0
PC3 Adenocarcinoma 420
LU65 Large-cell carcinoma 13
LK-2 Squamous-cell carcinoma 20
PC9
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Figure 1 Expression profiles of the sensitive cell line PC9 and resistant subpopulations PC9/f9 and PC9/f14 using cDNA array.
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scells in nude mice and subsequent culture of the tumour cells
harvested from pulmonary metastatic foci (Takenaka et al, 2000).
PC9/f14 was established by five additional inoculations (Gemma
et al, 2001). In the matrigel invasion assay, the PC9/f9 and PC9/f14
cells showed higher invasive activity than the parent PC9 cells
(data not shown). The resistance to gefitinib in PC9/f9 and PC9/f14
cells was therefore acquired naturally in the absence of exposure to
gefitinib.
cDNA array analysis in PC9, PC9/f9 and PC9/f14 cells
In order to identify potential key molecules for natural resistance
to gefitinib, we analysed the expression profiles of the PC9,
PC9/f9 and PC9/f14 cell lines using cDNA array, and examined
the effect of gefitinib on the EGF downstream mediators PI3K–Akt
and Ras/MEK/Erk. Significant enhancement of four and
eight genes was identified in the PC9/f9 and PC9/f14 cell
lines, respectively, compared with the parent cell line. Only
Galectin-1 was overexpressed in both of the resistant cell lines
and lactate dehydrogenase A was downregulated. There were
no significant differences in EGFR expression, nor were Ras,
PTEN, PI3K, Akt, Raf or ERK1/2 differentially expressed
(Figure 1).
Phosphorylation of Akt in PC9, PC9/f9 and PC9/f14 cells
We examined expression and phosphorylation (Ser473) of Akt in
PC9, PC9/f9 and PC9/f14 cells using Western blot analysis. There
were no significant differences in Akt expression between the
parent cell line and subpopulations. However, PC9/f9 and PC9/f14
cells demonstrated increased Akt phosphorylation compared with
PC9 cells (Figure 2).
Expression of PTEN in PC9, PC9/f9 and PC9/f14 cells
We also examined expression of PTEN, a phosphatase that can
dephosphorylyse position D3 of phosphatidylinositol-3,4,5 tripho-
sphatase and which is a major negative regulator of the PI3 kinase/
Akt signalling pathway (Cantley and Neel, 1999; Simpson and
Parsons, 2001). PC9 demonstrated moderate expression of PTEN
and there was minimal or absent expression of PTEN in PC9/f9
and PC9/f14 cells (Figure 3). Frequent homozygous deletion of the
PTEN gene has been reported in lung cancer (Kohno et al, 1998;
Ali et al, 1999; Vivanco and Sawyers, 2002), so we performed
screening of genomic DNA analysis by PCR. We detected no
homozygous deletions of the PTEN gene in any of the three
subpopulations of the cell line examined (Figure 4).
Expression and phosphorylation state of p38 MAP kinase
in PC9, PC9/f9 and PC9/f14 cells
We then examined the expression and phosphorylation state of
p38 MAP kinase in PC9, PC9/f9 and PC9/f14 cells. p38 MAP kinase
is activated by a variety of cellular stresses including osmotic
shock, inflammatory cytokines, ultraviolet light, and growth
factors. Phospho-p38 MAP kinase antibody detects p38 MAP
kinase only when activated by dual phosphorylation at Thr180 and
Tyr182. PC9 demonstrated activated p38 but only minimally
activated p38 was observed in PC9/f9 and PC9/f14 cells (Figure 5).
Mutation of EGFR gene in these cell lines
Polymerase chain reaction–SSCP analysis was performed on these
three lung cancer cell line subpopulations. The reported mutation
in the EGFR gene was detected in parent cell line, PC9 (Arao T,
et al, 2004), but no mutation were detected in PC9/f9 and PC9/f14
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Figure 2 Expression and phosphorylation state of Akt in the sensitive cell line PC9 and resistant subpopulations PC9/f9 and PC9/f14, and dose-dependent
effect of gefitinib.
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s(Figure 6). We performed karyotype analyses using multicolour
FISH analysis to confirm that these subpopulations have same
origin. The multicolour FISH analyses demonstrated that these
subpopulations had similar chromosome numbers and chromo-
somal rearrangements (at least, eight common rearrangements)
(Figure 7). These results showed that these subpopulations with
naturally acquired resistance to gefitinib lost the EGFR gene
mutation.
Effect of gefitinib on phosphorylation of Akt and p38 MAP
kinase and expression of PTEN
Using Western blot analysis, we also examined the effect of
gefitinib on PTEN expression, and expression and phosphoryla-
tion of Akt and p38 MAP kinase in PC9, PC9/f9 and PC9/f14 cells.
While gefitinib had no influence on Akt phosphorylation in PC9/f9
and PC9/f14 cells, it inhibited Akt phosphorylation in PC9 cells,
with complete inhibition of Akt phosphorylation observed at
gefitinib concentrations X0.1mM (44.7ngml
 1). Notably, this
concentration is substantially lower than that reported as the
minimal steady-state concentration in clinical trials (Ranson et al,
2002). In PC9 cells, gefitinib was associated with increased PTEN
expression, but there was absent or only minimal expression of
PTEN in PC9/f9 and PC9/f14 cells and gefitinib did not influence
expression. Gefitinib did not influence the expression or
phosphorylation state of p38 MAP kinase (Figures 2, 3 and 5).
DISCUSSION
Gefitinib exerts antitumour activity through inhibition of EGFR-
TK (Rusch et al, 1993; Salomon et al, 1995), but its antitumour
activity cannot be predicted by EGFR expression in tumours
(Bailey et al, 2003). Recent reports showing differences in the
frequency of activating mutations in the EGFR gene between
gefitinib responders and nonresponders suggest that these EGFR
mutations are predictive markers for sensitivity to gefitinib (Lynch
et al, 2004; Paez et al, 2004). However, there are also sensitive
tumors to gefitinib without the EGFR gene mutation. We examined
the sensitivity of various NSCLC cell lines to gefitinib using the
MTT assay and attempted to identify potential key molecules
involved in gefitinib resistance. We identified PC9, a parent
adenocarcinoma cell line sensitive to gefitinib, and two resistant
subpopulations, PC9/f9 and PC9/f14. As the artificial metastasis
method was used for subpopulation generation, PC9/f9 and PC9/
f14 had highly metastatic potential and natural resistance to
gefitinib.
We analysed the expression profiles using cDNA array,
genomic status of the EGFR gene, and examined the effect of
gefitinib on the downstream mediators of EGF-mediated signalling
PI3K–Akt and Ras/MEK/Erk (Olayioye et al, 2000) pathways in
these subpopulations. Both resistant subpopulations demonstrated
increased activation of Akt, reduced expression of PTEN and loss
of the EGFR gene mutation, compared with the parent cell line.
Gefitinib inhibited Akt phosphorylation in the gefitinib-sensitive
parent cell line but not in the resistant subpopulations PC9/f9 and
PC9/f14.
She et al (2003) reported that the MDA468 breast cancer cell
line, which lacks PTEN function, was resistant to gefitinib.
Reconstitution of PTEN function in MDA468 cells through tet-
inducible expression restored gefitinib sensitivity and re-estab-
lished EGFR-stimulated Akt signalling. Bianco et al (2003) also
reported that loss of PTEN in MDA468 counteracted the
antitumour action of EGFR-TK inhibitors and that restoration of
PTEN by retroviral infection was associated with gefitinib-
mediated inhibition of Akt phosphorylation, and increased
apoptosis and cell-cycle delay.
In accordance with these data, our results demonstrated loss of
PTEN protein and overactivation of Akt in NSCLC subpopulations
with highly metastatic potential and natural resistance to gefitinib,
PTEN
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Figure 3 Expression of PTEN in the sensitive cell line PC9 and resistant
subpopulations PC9/f9 and PC9/f14, and dose-dependent effect of gefitinib.
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Figure 4 Genomic DNA analysis of the PTEN gene in sensitive cell line
PC9 and resistant subpopulations PC9/f9 and PC9/f14.
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sand indicated that PTEN protein level and Akt phosphorylation
state may be additional key predictors of de novo resistance to
gefitinib. Reintroduction of PTEN or pharmacological down-
regulation of constitutive PI3K–Akt-pathway activity might
potentially sensitise lung carcinomas to gefitinib, although further
preclinical studies are required.
There are many reports of Akt-promoted tumour invasion and
metastasis. Park et al (2001) showed that Akt1 induced extra-
cellular matrix invasion and matrix metalloproteinase (MMP)-2
activity in mouse mammary epithelial cells. Kim et al (2001) also
demonstrated that Akt/protein kinase-B promoted cancer cell
invasion via increased motility and MMP production. Over-
expression of Akt2 was also reported to lead to upregulation of
beta-1 integrins and increased invasion and metastasis of human
breast and ovarian cancer cells by Arboleda et al (2003). We
established highly metastatic human lung adenocarcinoma cell
subpopulations, PC9/f9 and PC9/f14, in an experimental metastasis
model by repeated inoculation of PC9 cells in nude mice and
subsequent culture of the tumour cells that were harvested from
pulmonary metastatic foci. The PC9/f9 and PC9/f14 cells showed
higher invasive activity in the matrigel invasion assay than the
parent PC9 cells (data not shown). Our data indicated that loss of
PTEN and overactivation of Akt during the repeated process of
artificial metastasis were associated with increased invasive
activity and may have contributed to natural resistance to gefitinib.
Loss of the EGFR gene mutation in PC9/f9 and PC9/f14 indicated
that constitutive Akt phosphorylation by EGFR gene mutation
does not seem to be necessary in some cancer cells with other
additional mechanisms of activating Akt.
In the expression profile analysis using cDNA array, we
could identify several molecules that were significantly up- or
downregulated in the gefitinib-resistant subpopulations compared
with the parent cell line. However, while the resistant subpopula-
tions demonstrated increased activation of Akt and reduced
expression of PTEN in Western blot analysis, we could not
identify significant differences in PTEN and Akt using cDNA array.
Furthermore, Western blot analysis failed to demonstrate a
difference in Akt gene expression between parent and resistant
subpopulations. The failure to demonstrate homozygous deletions
of the PTEN gene in these subpopulations and differences in PTEN
mRNA levels between the sensitive and resistant cell subpopula-
tions indicates that the reduced PTEN protein expression in these
gefitinib-resistant cells may be the result of post-translational
regulation or partial genomic alterations. Our data indicate that, at
this time, gene expression profile analysis may not be sufficient for
the identification of potential key molecules in gefitinib resistance,
and protein expression and evaluation of phosphorylation status
may be more informative. The reduced phosphorylation of p38
observed in PC9/f9 and PC9/f14 cells in our study indicates that
gefitinib resistance may be affected through a negative feedback
mechanism.
Homozygous deletion of the PTEN gene has been reported in
lung cancer (Kohno et al, 1998; Ali et al, 1999; Vivanco and
Sawyers, 2002). The results of our study indicate that PTEN protein
expression and Akt phosphorylation may be candidate markers of
gefitinib sensitivity; conversely, lack of PTEN expression and Akt
phosphorylation may be candidate markers of gefitinib resistance.
Those tumours with activating mutations in the EGFR gene but
which lack PTEN may be resistant to gefitinib, as PTEN is located
downstream of the EGFR. Since Akt phosphorylation is influenced
by activating mutations in the EGFR gene and loss of PTEN
function, Akt phosphorylation alone could not be a secondary
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Figure 5 Expression and phosphorylation state of p38 MAP kinase in the sensitive cell line PC9 and resistant subpopulations PC9/f9 and PC9/f14, and
dose-dependent effect of gefitinib.
PTEN and EGFR gene mutation in NSCLC
Y Kokubo et al
1716
British Journal of Cancer (2005) 92(9), 1711–1719 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smarker of these EGFR mutations. More extensive clinical study
using biopsy samples may be useful for further evaluation of PTEN
protein expression as a marker for gefitinib sensitivity.
Finally, the EGFR gene mutation may be lost in some cancer
cells with other additional mechanisms of activating Akt. This
alteration might be a novel mechanism and/or marker for acquired
Control
(BET2A)
PC9 PC9/f9 PC9/f14
ex19
77 188
188 Exon19-PC9
(DelE746-A750)
Wild type 199
199
210
210
22
A
B
Figure 6 (A) Polymerase chain reaction–SSCP analysis of the EGFR gene in PC9, PC9/f9 and PC9/f14. Aberrant bands were shown only in PC9. (B)
Sequence of aberrant and normal bands. These sequence analyses showed deletion of the EGFR gene in PC9.
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sresistance to gefitinib. Reintroduction of PTEN or pharmacological
downregulation of the constitutive PI3K–Akt-pathway activity
may be an attractive therapeutic strategy in cancers without the
EGFR gene mutation. The existence of these cell line subpopula-
tions will facilitate investigation of EGF-mediated signalling PI3K–
Akt in human cancers.
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